Drugmakers Cut Yazen Fulfillment Margins
Yazen
Drug makers taking over the cash pay GLP-1 checkout turns Yazen from a reseller with margin into a care layer that has to justify its fee on outcomes. When Novo Nordisk and Eli Lilly sell branded medication directly at set monthly prices, the part of the workflow where a telehealth company sourced, marked up, and fulfilled the drug gets squeezed. That leaves Yazen competing on coaching, titration support, and clinical follow up rather than access alone.
-
Ro shows what the new market structure looks like. It now routes prescriptions into LillyDirect and NovoCare behind the scenes, while the manufacturers keep more of the economics and set the cash pay price floor at roughly $499 per month. That is the template that compresses intermediary pricing power across the category.
-
Yazen’s own workflow is more involved than a simple prescription pass through. It starts with screening, nurse consults, blood work, physician review, and a personalized plan in the app. That clinical layer still matters, but it is harder to bundle premium medication economics on top when branded supply is easier to buy elsewhere.
-
Comparable platforms are already feeling the same pressure. Numan is framed around rising price competition, reliance on wholesale branded GLP-1 supply, and stronger U.S. players with direct manufacturer relationships. As shortages ease, obesity telehealth starts to look less like a supply arbitrage business and more like a service business.
The next phase favors platforms that can prove they improve adherence, dose management, and long term weight loss, not just ship pens to a patient’s door. For Yazen, that means building a business where labs, clinician oversight, and coaching are the product, and medication fulfillment becomes a lower margin utility attached to it.